Evidence map›Paper›PMID 24475142›Full record

Trial reportPloS one2014

Randomized controlled ferret study to assess the direct impact of 2008-09 trivalent inactivated influenza vaccine on A(H1N1)pdm09 disease risk.

Danuta M Skowronski, Marie-Eve Hamelin, Gaston De Serres, Naveed Z Janjua, Guiyun Li, Suzana Sabaiduc, Xavier Bouhy, Christian Couture, Anders Leung, Darwyn Kobasa and 7 more

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Evidence in a Cluster Randomized Controlled Trial of Increased 2009 Pandemic Risk Associated With 2008-2009 Seasonal Influenza Vaccine Receipt.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019
    Article
  9. Paradoxical clade- and age-specific vaccine effectiveness during the 2018/19 influenza A(H3N2) epidemic in Canada: potential imprint-regulated effect of vaccine (I-REV).Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2019
    Article
  10. Review
  11. Article
  12. Article
  13. Viral-Induced Enhanced Disease Illness.Frontiers in microbiology · 2018
    Review
  14. Article
  15. Article
  16. Article
  17. A Perfect Storm: Impact of Genomic Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014-2015 Season.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016
    Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 9 institutions in 2 countries.

Danuta M SkowronskiBritish Columbia Centre for Disease Control, Vancouver, British Columbia, Canada ; University of British Columbia, Vancouver, British Columbia, Canada.
Marie-Eve HamelinCentre Hospitalier Universitaire de Québec [University Hospital Centre of Québec], Québec, Canada ; Laval University, Québec, Canada.
Gaston De SerresCentre Hospitalier Universitaire de Québec [University Hospital Centre of Québec], Québec, Canada ; Laval University, Québec, Canada ; Institut National de Santé Publique du Québec [National Institute of Health of Québec], Québec, Canada.
Naveed Z JanjuaBritish Columbia Centre for Disease Control, Vancouver, British Columbia, Canada ; University of British Columbia, Vancouver, British Columbia, Canada.
Guiyun LiBritish Columbia Centre for Disease Control, Vancouver, British Columbia, Canada.
Suzana SabaiducBritish Columbia Centre for Disease Control, Vancouver, British Columbia, Canada ; University of British Columbia, Vancouver, British Columbia, Canada.
Xavier BouhyCentre Hospitalier Universitaire de Québec [University Hospital Centre of Québec], Québec, Canada.
Christian CoutureInstitut universitaire de cardiologie et pneumologie de Québec, Québec, Québec, Canada.
Anders LeungPublic Health Agency of Canada, Winnipeg, Manitoba, Canada.
Darwyn KobasaPublic Health Agency of Canada, Winnipeg, Manitoba, Canada ; Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada.
Carissa Embury-HyattCanadian Food Inspection Agency, Winnipeg, Manitoba, Canada.
Erwin de BruinLaboratory for Infectious Disease Research, Diagnostics and Screening, Centre for Infectious Disease Control (CIDC), Rijksinstituut voor Volksgezondheid en Milieu (RIVM) [National Institute of Public Health and the Environment], Bilthoven, The Netherlands.
Robert BalshawBritish Columbia Centre for Disease Control, Vancouver, British Columbia, Canada ; University of British Columbia, Vancouver, British Columbia, Canada ; Simon Fraser University, Burnaby, British Columbia, Canada.
Sophie LavigneInstitut universitaire de cardiologie et pneumologie de Québec, Québec, Québec, Canada.
Martin PetricBritish Columbia Centre for Disease Control, Vancouver, British Columbia, Canada ; University of British Columbia, Vancouver, British Columbia, Canada.
Marion KoopmansLaboratory for Infectious Disease Research, Diagnostics and Screening, Centre for Infectious Disease Control (CIDC), Rijksinstituut voor Volksgezondheid en Milieu (RIVM) [National Institute of Public Health and the Environment], Bilthoven, The Netherlands ; Viroscience Department, Erasmus MC, Rotterdam, The Netherlands.
Guy BoivinCentre Hospitalier Universitaire de Québec [University Hospital Centre of Québec], Québec, Canada ; Laval University, Québec, Canada.
BC Centre for Disease Control · CACentre hospitalier universitaire de Québec · CAInstitut universitaire de cardiologie et de pneumologie de Québec · CAPublic Health Agency of Canada · CAUniversité Laval · CAUniversity of British Columbia · CACanadian Food Inspection Agency · CAErasmus University Rotterdam · NLNational Institute for Public Health and the Environment · NL

Funding

Canadian Institutes of Health Research 229733
6 · The paper itself

Abstract

During spring-summer 2009, several observational studies from Canada showed increased risk of medically-attended, laboratory-confirmed A(H1N1)pdm09 illness among prior recipients of 2008-09 trivalent inactivated influenza vaccine (TIV). Explanatory hypotheses included direct and indirect vaccine effects. In a randomized placebo-controlled ferret study, we tested whether prior receipt of 2008-09 TIV may have directly influenced A(H1N1)pdm09 illness. Thirty-two ferrets (16/group) received 0.5 mL intra-muscular injections of the Canadian-manufactured, commercially-available, non-adjuvanted, split 2008-09 Fluviral or PBS placebo on days 0 and 28. On day 49 all animals were challenged (Ch0) with A(H1N1)pdm09. Four ferrets per group were randomly selected for sacrifice at day 5 post-challenge (Ch+5) and the rest followed until Ch+14. Sera were tested for antibody to vaccine antigens and A(H1N1)pdm09 by hemagglutination inhibition (HI), microneutralization (MN), nucleoprotein-based ELISA and HA1-based microarray assays. Clinical characteristics and nasal virus titers were recorded pre-challenge then post-challenge until sacrifice when lung virus titers, cytokines and inflammatory scores were determined. Baseline characteristics were similar between the two groups of influenza-naïve animals. Antibody rise to vaccine antigens was evident by ELISA and HA1-based microarray but not by HI or MN assays; virus challenge raised antibody to A(H1N1)pdm09 by all assays in both groups. Beginning at Ch+2, vaccinated animals experienced greater loss of appetite and weight than placebo animals, reaching the greatest between-group difference in weight loss relative to baseline at Ch+5 (7.4% vs. 5.2%; p = 0.01). At Ch+5 vaccinated animals had higher lung virus titers (log-mean 4.96 vs. 4.23pfu/mL, respectively; p = 0.01), lung inflammatory scores (5.8 vs. 2.1, respectively; p = 0.051) and cytokine levels (p>0.05). At Ch+14, both groups had recovered. Findings in influenza-naïve, systematically-infected ferrets may not replicate the human experience. While they cannot be considered conclusive to explain human observations, these ferret findings are consistent with direct, adverse effect of prior 2008-09 TIV receipt on A(H1N1)pdm09 illness. As such, they warrant further in-depth investigation and search for possible mechanistic explanations.

Indexed as

Analysis of VarianceAnimalsAntibodies, ViralEnzyme-Linked Immunosorbent AssayFerretsHemagglutination TestsImmunohistochemistryInfluenza A Virus, H1N1 SubtypeInfluenza VaccinesMicroarray AnalysisNeutralization TestsOrthomyxoviridae InfectionsVaccines, InactivatedAntibodies, ViralInfluenza VaccinesVaccines, Inactivated

Identifiers

PMID24475142
PMCPMC3903544
OpenAlexW2063445611

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.